Immunogenicity and safety of COVID-19 subunit vaccine Nanocovax in animal models
Sumary of Immunogenicity and safety of COVID-19 subunit vaccine Nanocovax in animal models:
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronavirus, has become a global health emergency.
On the 14th post-priming injection day, total specific IgG levels were determined using ELISA.
Related StoriesNorthern pig-tailed macaques were used to test the Nanocovax vaccine’s immunogenicity.
Monkeys were given Nanocovax at various dosages twice through Intramuscular injection or PBS as a negative control.
Blood samples were taken on days 14, 28, and 45 after the booster injection on day 7 to assess antibody levels.
The levels of S protein-specific IgG in the 25-, 50-, 75-, and 100-g groups were marginally higher on day 28 after priming injection than in the control group, at 39.02-fold, 68.58-fold, 87.82-fold, and 97.37-fold, respectively, than in the control group.
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
